FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/AMGN
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Amgen, Inc. (AMGN) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Amgen (AMGN) trades at $451.83, up 0.87% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with 22.95% net margin and 91.47% ROE, though valuations appear elevated at 28.06 P/E. Recent Phase 3 success for dazodalibep in Sjögren's disease and dividend increases highlight positive developments, while high debt levels and competitive pressures remain considerations.
Amgen presents a compelling growth story with strong profitability and pipeline progress, though current price exceeds analyst consensus target. The combination of operational strength, dividend growth, and clinical successes supports upside potential, balanced by valuation concerns and significant leverage that could constrain flexibility in a rising rate environment.
Read full analysis

Key Stats

  • Market Cap
    $244.27B
  • Volume
    2,812,745
  • Sector
    Health
  • 52W High
    $460.73
  • 52W Low
    $292.00
  • Typical Hold Time
    73 Days
  • Enterprise Value
    $287.59B
  • Div Yield
    2.23%
  • Trading Activity
    46% Sell | 54% Buy
$473.8
52W Low: $292
30 Oct 2025
52W High: $473.8
30 Oct 2026

Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $292 and a high of $473.8, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Most Recent News

Content is generated by Aura AI

BlackRock surpasses 5% ownership in Tryg A/S, triggering major shareholder disclosure.

BlackRock, Inc. has notified Tryg A/S that it now holds more than 5% of the company's shares and voting rights, according to the Capital Markets Act. This significant stake requires public disclosure and highlights BlackRock's growing influence in Tr...

Market News
41 minutes ago
Na
Neutral
BlackRock surpasses 5% ownership in Tryg A/S, triggering major shareholder disclosure.

BlackRock acquires over 5% stake in Tryg A/S, signaling significant investor interest.

BlackRock, Inc. has announced it acquired shares and voting rights exceeding 5% of the total issued share capital and voting rights in Tryg A/S, a major insurance company. This move, disclosed under Danish capital market laws, indicates BlackRock's g...

Market News
41 minutes ago
Na
Neutral
BlackRock acquires over 5% stake in Tryg A/S, signaling significant investor interest.

Virtus Total Return Fund rated Hold due to high leverage and dividend risks despite 10% yield.

The Virtus Total Return Fund (ZTR) is rated Hold because of its high leverage at 31%, concerns about the sustainability of its dividend, and a discount near its historical average. Although ZTR offers an attractive 10% yield and trades at a 9.9% disc...

Market News
4 hours ago
Seeking Alpha
Bearish
news icon
Virtus Total Return Fund rated Hold due to high leverage and dividend risks despite 10% yield.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $244.27B
  • Volume
    2,812,745
  • Sector
    Health
  • 52W High
    $460.73
  • 52W Low
    $292.00
  • Typical Hold Time
    73 Days
  • Enterprise Value
    $287.59B
  • Div Yield
    2.23%
  • Trading Activity
    46% Sell | 54% Buy
$473.8
52W Low: $292
30 Oct 2025
52W High: $473.8
30 Oct 2026

Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $292 and a high of $473.8, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!